Should we still advise infertile couples to use (barrier) contraception before IVF down-regulation?

Fertility and Sterility

Volumn 74, Issue 4, 2000, Pages 655-659

  Platteau, Peter ^a,d   Gabbe, Maria ^b   Famelos, Martha ^c   Kovacs, Gabor ^d   Healy, David ^a  

^a MONASH IVF   (Australia)

^b Mercy Assisted Conception Clinic   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

GnRH a; IVF; Luteolysis; Nafarelin; Pregnancy; Teratogenicity

Indexed keywords

BUSERELIN; GONADORELIN AGONIST; LEUPRORELIN; NAFARELIN;

ARTICLE; CLINICAL PROTOCOL; CONTRACEPTION; DOWN REGULATION; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; LUTEAL PHASE; MAJOR CLINICAL STUDY; PREGNANCY COMPLICATION; PRIORITY JOURNAL;

AUSTRALIA; BARRIER METHODS; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE METHODS; DEVELOPED COUNTRIES; FAMILY PLANNING; FERTILIZATION; IN VITRO; OCEANIA; PREGNANCY; PREGNANCY OUTCOMES; REPRODUCTION; RESEARCH METHODOLOGY; RESEARCH REPORT; RETROSPECTIVE STUDIES; STUDIES;

BUSERELIN; DOWN-REGULATION; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; LEUPROLIDE; MALE; NAFARELIN; OUTCOME ASSESSMENT (HEALTH CARE); PREGNANCY; RETROSPECTIVE STUDIES;

EID: 0033800242     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)01524-7     Document Type: Article

References (62)

1. Daya S. Optimal GnRH agonist protocol [abstract]. (10th World Congress on IVF and Assisted Reproduction.) J Assist Reprod Genet 1997;14 Suppl:PS-26-3.
2. Kondaveeti-Gordon U, Harrison R, Barry-Kinsella C, Gordon A, Drudy L, Cottell E. A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotropin-releasing hormone in an in vitro fertilization program. Fertil Steril 1996;66:582-86.
3. Herman A., Ron-El R., Golan A., Nahum H., Soffer Y., Caspi E. Follicle cysts after menstrual versus midluteal administration of gonadotropin-releasing hormone analog in in vitro fertilization. Fertil Steril. 53:1990;854-858.
4. Barlow D. GnRH agonists and in vitro fertilisation. J Reprod Med. 43:1998;245-245.
5. Balasch J., Martinez F., Jove I., Cabre L., Coroleu B., Barri P.N., et al. Inadvertent gonadotrophin-releasing hormone agonist (GnRHa) administration in the luteal phase may improve fecundity in in-vitro fertilization patients. Hum Reprod. 8:1993;1148-1151.
6. Dicker D., Goldman J.A., Vagman I., Eckstein N., Ayalon D. Pregnancy outcome following early exposure to maternal luteinizing-hormone-releasing hormone agonist (buserelin). Hum Reprod. 4:1989;250-251.
7. Martinez F., Barri P.N., Coroleu V. Case report accidental GnRH agonist administration during early pregnancy . Hum Reprod. 3:1988;669.
8. Serafini P., Batzofin J., Kerin J., Marrs R. Pregnancy a risk to initiation of leuprolide acetate during the luteal phase before controlled ovarian hyperstimulation . Fertil Steril. 50:1988;371-372.
9. Chetkowski R., Kruse L., Nass T. Improved pregnancy outcome with the addition of leuprolide acetate to gonadotropins for in vitro fertilization. Fertil Steril. 52:1989;250-255.
10. Forman R., Robinson J., Egan D., Ross C., Gosden B., Barlow D. Ectopic pregnancy after luteal phase initiation of gonadotropin-releasing hormone analog before in vitro fertilisation. Fertil Steril. 54:1990;169-170.
11. Golan A., Ron-El R., Herman A., Weinraub Z., Soffer Y., Caspi E. Fetal outcome following inadvertant administration of long-acting DTRP6 GnRH microcapsules during pregnancy a case report . Hum Reprod. 5:1990;123-124.
12. Isherwood P.J., Ibrahim Z.H.Z., Matson P.L., Morroll D.R., Burslem R.W., Lieberman B.A. Endocrine changes in women conceiving during treatment with an LHRH agonist. Hum Reprod. 5:1990;409-412.
13. Ron-El R., Golan A., Herman A., Raziel A., Soffer Y., Caspi E. Midluteal gonadotropin-releasing hormone analog administration in early pregnancy. Fertil Steril. 53:1990;572-574.
14. Lejeune B., Barlow P., Puissant F., Delvigne A., Vanrysselberge M., Leroy F. Use of buserelin acetate in an in vitro fertilization program a comparison with classical clomiphene citrate-human menopausal gonadotropin treatment . Fertil Steril. 54:1990;475-481.
15. Smitz J., Camus M., Devroey P., Bollen N., Tournaye H., Van Steirteghem A. The influence of inadvertent intranasal buserelin administration in early pregnancy. Hum Reprod. 6:1991;290-293.
16. Ghazi D.M., Kemmann E., Hammond J.M. Normal pregnancy outcome after early maternal exposure to gonadotropin releasing hormone agonist. A case report. J Reprod Med. 36:1991;173-174.
17. Herman A., Ron-El R., Golan A., Nachum H., Soffer Y., Caspi E. Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone. Hum Reprod. 7:1992;465-468.
18. Lockwood G., Robinson J., Barlow D. Pregnancy outcome following inadvertent luteal phase initiation of gonadotropin-releasing hormone agonist (GnRH-a) treatment in superovulation cycles. [Abstract] J Reprod Fertil. 10:1992;4.
19. Rocco V. Fetal outcome following "accidental" administration of a long-acting DTRP6 GnRh depot preparation during the first trimester of pregnancy. Minerva Ginecol. 44:1992;585-586.
20. Jackson A.E., Curtis P., Amso N., Shaw R.W. Exposure to LHRH agonist in early pregnancy following the commencement of mid-luteal buserelin for IVF stimulation. Hum Reprod. 7:1992;1222-1224.
21. Shulman A, Shilon M, Bahary C, Dor J, Ellenbogen A, Mashiach S. Inadvertent exposure of early pregnancy to gonadotropin releasing hormone analogue. J Assist Reprod Genet 1993;10:387-91.
22. Gonen Y., Dirnfeld M., Abramovici H. Outcome of pregnancies inadvertently exposed to gonadotropin-releasing hormone analogues (GnRH-a) in early gestation. J Assist Reprod Genet. 10:1993;437-439.
23. Har-Toov J, Brenner SH, Jaffa A, Yavetz H, Peyser MR, Lessing JB. Pregnancy during long-term gonadotropin-releasing hormone agonist therapy associated with clinical pseudomenopause. Fertil Steril 1993;59:446-7.
24. Weissman A., Shoham Z. Favourable pregnancy outcome after administration of a long-acting gonadotrophin-releasing hormone agonist in the mid-luteal phase. Hum Reprod. 8:1993;496-497.
25. Wilshire G., Emmi A., Gagliardi C., Weiss G. Gonadotrophin-releasing hormone agonist administration in early human pregnancy is associated with normal outcomes. Fertil Steril. 60:1993;980-983.
26. Young D.C., Snabes M.C., Poindexter A.N. GnRH agonist exposure during the first trimester of pregnancy. Obstet Gynecol. 81:1993;587-589.
27. Pickersgill A., Kingsland C., Garden A., Farquharson R. Multiple gestation following gonadotrophin releasing hormone therapy for the treatment of minimal endometriosis. Br J Obstet Gynaecol. 101:1994;260-262.
28. Cahill D.J., Fountain S.A., Fox R., Fleming C.F., Brinsden P.R., Hull M.G.R. Outcome of inadvertent administration of a gonadotrophin-releasing hormone agonist (buserelin) in early pregnancy. Hum Reprod. 9:1994;1243-1246.
29. Abu-Heija A.T., Fleming R., Yates R.W.S., Coutts J.R.T. Pregnancy outcome following exposure to gonadotrophin-releasing hormone analogue during early pregnancy comparisons in patients with normal or elevated luteinizing hormone . Hum Reprod. 10:1995;3317-3319.
30. Chang S.Y., Soong Y. Unexpected pregnancies exposed to leuprolide acetate administered after the mid-luteal phase for ovarian stimulation. Hum Reprod. 10:1995;204-206.
31. Elefant E., Biour B., Blumberg-Tick J., Roux C., Thomas F. Administration of a gonadotropin-releasing hormone agonist during pregnancy follow-up of 28 pregnancies exposed to triptoreline . Fertil Steril. 63:1995;1111-1113.
32. Uncu G, Benderli S, Esmer A. Pregnancy during gonadotrophin-releasing hormone agonist therapy. Aust N Z J Obstet Gynaecol 1996;36:484.
33. Gartner B., Moreno C., Marinaro A., Remohi J., Simon C., Pellicer A. Accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration and pregnancy in an in-vitro fertilization cycle. Hum Reprod. 12:1997;2557-2559.
34. Goitia M, Matorras R, Uruena J, Aurrekoetxea B, Diez S, Rodriguez-Esudero FJ. Inadvertent exposure to GnRH agonists during early pregnancy [Abstract]. Hum Reprod 1997;12:R-214,327.
35. Egbase PE, Al-Sharhan MS, Grudzinskas JG. The outcome of pregnancies conceived spontaneously in the index cycle of luteal phase long protocol pituitary down regulation prior to commencement of controlled ovarian stimulation for IVF-ET. MEFSJ 1998;3:154-6.
36. Hemmings R., Biljan M., Dean N., Tan S. An ectopic pregnancy masked by follicular initiation of gonadotropin-releasing hormone agonist for pituitary desensitization prior to in vitro fertilization. J Assist Reprod Genet. 15:1998;161-163.
37. Chardonnens D., Sylvan K., Walker D., Bischof P., Sakkas D., Campana A. Triptorelin acetate administration in early pregnancy case reports and review of the literature . Eur J Obstet Gynecol Reprod Biol. 80:1998;143-149.
38. Cahill D. Risks of GnRH agonist administration in early pregnancy. Filicori M., Flamigni C. Ovulation induction, update '98. 1998;97-105 Parthenon, New York.
39. Hull M., Glazener C., Kelly N. Population study of causes, treatment and outcome of infertility. Br Med J. 291:1985;1693-1697.
40. Balasch J., Gomez F., Casamitjana R., Carmona F., Rivera F., Vanrell J. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Hum Reprod. 7:1992;1230-1234.
41. Jansen R. Spontaneous abortion incidence in the treatment of infertility. Am J Obstet Gynecol. 143:1982;451-473.
42. Chong A., Keene M., Forte C., Dileo P., Brown P., McGary J. Incidence of spontaneous abortion among treated infertility patients. Int J Fertil. 36:1991;219-221.
43. Hay D, Lopata A. Chorionic gonadotropin secretion by human embryos in vitro. J Clin Endocrinol Metab 1988;67:1322-4.
44. Clayton R., Harwood J., Catt K. Gonadotropin-releasing hormone analogue binds to luteal cells and inhibits progesterone production. Nature. 282:1979;90-92.
45. Tureck R., Mastroianni L., Blasco L., Strauss J. Inhibibition of human granulosa cell progesterone secretion by a gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 54:1982;1078-1080.
46. Torok A., Hamori M., Bodis J. Effect of LHRH and its analogues on the progesterone secretion of human granulosa cells in vitro. Gynecol Obstet Invest. 34:1992;222-224.
47. Casper R., Erickson G., Yen S. Studies on the effect of GnRH and its agonist on human luteal steroidogenesis in vitro. Fertil Steril. 42:1984;39-43.
48. Kang I.S., Kuehl T.J., Siler-Khodr T.M. Effect of treatment with gonadotropin-releasing hormone analogues on pregnancy outcome in the baboon. Fertil Steril. 52:1989;846-853.
49. Vickery BH, McRae GI, Stevens VC. Suppression of luteal and placental function in pregnant baboons with agonist analogs of luteinizing hormone-releasing hormones. Fertil Steril 1981;36:664-8.
50. Eley R. The effect of LHRH analogs on pregnancy in the baboon. contraception. 35:1987;389-393.
51. Bergquist C., Nillius J., Wide L. Effects of a luteinizing hormone-releasing hormone agonist on luteal function in women. Contraception. 22:1980;287-293.
52. Casper R, Sheehan K, Yen S. Chorionic gonadotropin prevents LRF-agonist-induced luteolysis in the human. Contraception 1980;21:471-8.
53. Tolis G., Comaru-Schally A.M., Mehta A.E., Schally A.V. Failure to interrupt established pregnancy in humans by D-tryptophan-6-luteinising hormone-releasing hormone. Fertil Steril. 36:1981;241-242.
54. Skarin G., Nillius S., Wide L. Failure to induce early abortion by huge doses of a superactive LRH agonist in women. Contraception. 26:1982;457-463.
55. French F., Bierman J. Probability of fetal mortality. Public Health Rep. 77:1960;835-847.
56. Sopelak V., Hodgen G. Infusion of gonadotropin-releasing hormone agonist during pregnancy maternal and fetal responses in primates . Am J Obstet Gynecol. 156:1987;755-760.
57. Thomas G., McNeilly A., Gibson F., Brooks A. Effects of pituitary-gonadal suppression with a gonadotrophin-releasing hormone agonist on fetal gonadotrophin secretion, fetal gonadal development and maternal steroid secretion in the sheep. J Endocrinol. 141:1994;317-324.
58. Sandrow J. Clinical applications of LHRH and its analogues. Clin Endocrinol. 18:1983;571-592.
59. Shepard T. Human teratogenicity. Adv Pediatr. 33:1986;225-268.
60. Happ J, Schultheiss H, Jacobi G. Pharmacodynamics, pharmacokinetics and bioavailability of prolonged LH-RH agonist decapeptyl-SR. In: Klijn J, ed. Hormonal manipulation of cancermograph. Series of the European organisation for research on treatment of cancer, Vol 18. New York: Raven Press, 1987:249.
61. Kaplan S., Grumbach M., Aubert M. The ontogenesis of pituitary hormones and hypothalamic factors in the human fetus maturation of central nervous system regulation of anterior pituitary function . Recent Prog Horm Res. 32:1976;161-243.
62. Diedrich K., Felberbaum R. New approaches to ovarian stimulation. Hum Reprod. 13:(Suppl 3):1998;1-13.